35results about How to "High potency" patented technology

The invention relates to a Nipah virus N protein specific monoclonal antibody as well as a preparation method and application thereof. The nipah virus specific monoclonal antibody is prepared by immunizing nipah virus N protein, the amino acid sequence of the nipah virus N protein is as shown in SEQ ID NO.2, the nipah virus N protein is obtained by transcription of a nipah virus N gene, and the nucleotide sequence of the nipah virus N gene is as shown in SEQ ID NO.1. The nipah virus specific monoclonal antibody has the advantages that the nipah virus specific monoclonal antibody is prepared by immunizing the nipah virus N protein; the monoclonal antibody with the nipah virus N protein specificity can be specifically combined with the nipah virus N protein and is high in titer and good in affinity, meanwhile, a detection kit prepared based on the antibody can effectively carry out nipah virus detection, and technical support can be provided for epidemiological monitoring and diagnosis of nipah virus infection.

The invention discloses a chimeric PEDV (porcine epidemic diarrhea virus) infectious clone plasmid, a PEDV chimeric virus as well as a construction method and application thereof. According to the invention, a PEDV genome is used as a skeleton for the first time, the chimeric virus for expressing the extracellular domain of the TGEV S protein is successfully rescued, and it is found that the TCID50 of the chimeric virus for expressing the extracellular domain of the TGEV S protein can be increased by 6.2 times compared with that of the chimeric PEDV for expressing the TGEV S protein. The recombinant virus is used as an inactivated vaccine for immunizing mice, so that the immunogenicity of TGEV S protein can be greatly improved, a body is stimulated to generate a higher-level neutralizing antibody aiming at TGEV, and the titer of the neutralizing antibody aiming at TGEV is improved by 16.8 times. Therefore, more possibilities are provided for modification of viral genomes, a novel method for improving immunogenicity of the TGEV inactivated vaccine is invented, and a basis is provided for research and development of the TGEV vaccine.

The invention relates to the technical field of biology, and aims to provide a monoclonal antibody 27E7 for resisting PCV2Cap protein as well as a preparation method and an application method of the monoclonal antibody 27E7. The monoclonal antibody comprises Ig structural domains VH CDR1, VH CDR2 and VH CDR3 of a heavy chain of the antibody, and Ig structural domains VL CDR1, VL CDR2 and VL CDR3 of a light chain of the antibody, wherein the amino acid sequences of the VH CDR1, the VH CDR2 and the VH CDR3 are respectively as shown in SEQ ID NO: 1 to SEQ ID NO: 3; the amino acid sequences of the VL CDR1, the VL CDR2 and the VL CDR3 are respectively as shown in SEQ ID NO: 4 to SEQ ID NO: 6. The monoclonal antibody provided by the invention is an IgG1 subtype, and has the advantages of high titer, strong specificity, high affinity and the like; the kit has high sensitivity and strong specificity, and has no cross reaction with other genotypes of porcine circoviruses; the kit can be further used for development of PCV2 diagnostic kits, and can be effectively popularized and applied to PCV2 diagnosis.

The invention discloses a wide-spectrum bacteriophage EFH2 capable of eliminating enterococcus faecalis suffering from humans and animals, and relates to the technical field of biology. The wide-spectrum bacteriophage is preserved in the China Center for Type Culture Collection on September 26, 2024, and the preservation number of the wide-spectrum bacteriophage is CCTCC NO: M 20242087. The wide-spectrum bacteriophage EFH2 is a newly found bacteriophage, has good tolerance under the conditions that the pH is 3-9 and the temperature is 4-60 DEG C, and has the titer as high as 2.31 * 10 < 8 > PFU / mL after being cultured for 8 hours under the condition that the MOI is 0.01. The wide-spectrum bacteriophage EFH2 is wide in antibacterial spectrum, short in incubation period, high in outbreak amount, capable of rapidly killing host bacteria, small in toxic and side effect, high in safety, wide in temperature and acid-base tolerance range, good in hydrophilicity and capable of well killing and disinfecting animals infected with multi-drug-resistant enterococcus and environments and food polluted by enterococcus.

The invention provides an anti-glycocholic acid antibody and application thereof, and particularly relates to more than ten positive monoclonal hybridoma cell strains obtained by adopting glycocholic acid antigen immune BALB / C mice and screening. Through performance determination, three cell strains capable of being specifically combined with glycocholic acid are finally obtained. Wherein the H15 antibody is high in titer, good in stability and stable in detection linearity, and can be used for clinical detection of glycocholic acid.

The invention discloses a high temperature resistant pigeon-source Salmonella typhimurium phage, a phage composition and an application thereof, wherein the high temperature resistant pigeon-source Salmonella typhimurium phage is named PC204, and its deposit number is CGMCC No. 22368. The phage PC204 belongs to a long-tailed phage, has the characteristics of high temperature resistance, exhibits strong lysis and wide lysis spectrum characteristics to pigeon-source Salmonella typhimurium, can effectively prevent and treat pigeon-source Salmonella typhimurium diseases, has a specific lysis advantage to the pigeon-source Salmonella typhimurium, and can effectively reduce the mortality rate of pigeons and the positive rate of pigeon-source typhoid antibodies. It can be prepared into drugs for preventing and treating pigeon paratyphoid disease, environmental disinfectants, pigeon feed and pigeon water additives, and detection kits for application. The phage is safe and has no toxic side effects, will not produce drug-resistant bacteria, and has a good market application prospect.

The invention relates to the technical field of immunization. The invention discloses parabacteroides dieldrii and parabacteroides goldsteinii, an application of the parabacteroides dieldrii and / or the parabacteroides goldsteinii in preparation of an immunopotentiator of a vaccine, and the immunopotentiator of the vaccine, and particularly discloses the parabacteroides dieldrii and the parabacteroides goldsteinii, the application of the parabacteroides dieldrii and / or the parabacteroides goldsteinii in preparation of the immunopotentiator of the vaccine. The parabacteroides dieldrii and / or the parabacteroides gold can be used as an immunopotentiator, can activate immunity, enhance antibody titer and shorten antibody generation reaction time, and can remarkably promote proliferation of B cells, plasma cells and memory B cell subgroups in a hair growth center.

The present application provides a recombinant protein antigen of Acinetobacter baumannii BA71_01558, a preparation method and its application, and relates to the field of biomedical technology. The amino acid sequence of the recombinant protein antigen of Acinetobacter baumannii BA71_01558 of the present invention is shown in SEQ ID NO.1. The preparation process of the recombinant protein antigen of Acinetobacter baumannii BA71_01558 provided by the present application is simple, the operation steps are easy to control and easy to implement, and the obtained recombinant protein of Acinetobacter baumannii BA711_01558 has a high purity and a high yield, and is suitable for large-scale production. The vaccine prepared using the recombinant protein antigen of Acinetobacter baumannii BA711_01558 of the present application has no toxic side effects, can produce high-titer antibodies, has a good immune protection effect against Acinetobacter baumannii infection, and is suitable for preparing specific antibodies.

The invention belongs to the field of microbial engineering, and provides a gentamicin C1a high-yield biological manufacturing method based on metabolic network modeling and reverse metabolic engineering renovation, which comprises the following steps: S1, constructing a genome scale metabolic model of a target production strain, predicting and screening a first target gene in positive correlation with gentamicin biosynthesis by using the model; s2, performing whole genome sequencing on the gentamicin high-yield mutant strain, and identifying a second target gene related to the high-yield character through comparative genomics analysis; s3, combining the first target gene predicted in the step S1 and the second target gene identified in the step S2, and constructing to obtain a recombinant engineering strain; s4, carrying out fermentation culture on the recombinant engineering strain, and supplementing materials in the fermentation process; by remarkably improving the production efficiency and strain performance of gentamicin C1a, important technical support and theoretical basis are provided for green biological manufacturing of antibiotics.

The invention provides a bacteriophage freeze-drying protective agent, a bacteriophage freeze-drying powder, a preparation method and application, and belongs to the technical field of biological medicine preparations. The freeze-drying protective agent comprises the following components: a cryoprotectant, an antioxidant, an acid-base regulator and a filler. The freeze-drying protective agent disclosed by the invention is reasonably compounded, and the freeze-drying protective agent, the antioxidant, the pH regulator and the filler have a good protective effect on the bacteriophage through a synergistic effect, so that the inactivation rate or the death rate of the bacteriophage in a freeze-drying process can be effectively reduced, and the biological activity and the titer of the bacteriophage are improved. Moreover, the freeze-drying protective agent disclosed by the invention is relatively long in protective effect acting time, can improve the stability of the freeze-dried powder of the bacteriophage, improves the transportation and storage convenience of the freeze-dried powder of the bacteriophage, and effectively solves the problem that the freeze-dried powder of the bacteriophage is difficult to transport and store for a long time in practical application.

The present application relates to a kind of mycophenolic acid detection reagent and its preparation and detection method, specifically a kind of mycophenolic acid chemiluminescence immunoassay reagent and its preparation and detection method, comprising: anti mycophenolic acid specific antibody, for detecting the indicating reagent of anti mycophenolic acid specific antibody-mycophenolic acid combination;The above anti mycophenolic acid specific antibody is obtained by mycophenolic acid immunogen immunization animal.The present application has the advantages that: the mycophenolic acid immunogen of the present application is specific, and immunogenicity is high, and the prepared anti mycophenolic acid specific antibody is specific, and titer is high;Chemiluminescence immunoassay reagent containing the above anti mycophenolic acid specific antibody can determine the mycophenolic acid content in sample conveniently, quickly and accurately, and multiple samples can be simultaneously determined on full-automatic chemiluminescence immunoassay analyzer, realize the high-throughput rapid determination of mycophenolic acid, and the accuracy is high, and the specificity is strong, and accuracy and detection efficiency have been greatly improved.

The present invention belongs to the field of biological detection, and discloses a monoclonal antibody for specific detection of MMP12 protein and its application. The monoclonal antibody for specific detection of MMP12 protein comprises a heavy chain variable region as shown in SEQ ID NO.7 and a light chain variable region as shown in SEQ ID NO.8. The monoclonal antibody for specific detection of MMP12 protein provided by the present invention has good biological activity, strong specificity, high titer, high sensitivity, and no cross-reactivity with other antigens, and has broad application prospects. The present invention also discloses a kit for specific detection of MMP12 protein, comprising the above-mentioned monoclonal antibody for specific detection of MMP12 protein, which can be used for specific detection of MMP12 protein in serum or whole blood, and can be used as an auxiliary diagnostic means for cancers with high expression of MMP12 protein, and has the advantages of simple detection method, high accuracy and low cost.

This invention discloses a monoclonal antibody against amide alcohol drugs and its applications, belonging to the field of biotechnology. The monoclonal antibody against an amide alcohol drug includes a heavy chain variable region and a light chain variable region. The amino acid sequences of CDR1, CDR2, and CDR3 in the heavy chain variable region are shown in SEQ ID No. 5 to SEQ ID No. 7, respectively; the amino acid sequences of CDR1, CDR2, and CDR3 in the light chain variable region are shown in SEQ ID No. 8 to SEQ ID No. 10, respectively. This invention provides a high-titer, high-sensitivity monoclonal antibody against amide alcohol drugs. Test strips based on this antibody exhibit high sensitivity, providing strong technical support for the detection of amide alcohol drug residues, drug development, and quality control.

The present application provides a recombinant protein antigen of Acinetobacter baumannii TonB, a preparation method and its application, and relates to the field of biomedical technology. The amino acid sequence of the recombinant protein antigen of Acinetobacter baumannii TonB of the present invention is shown in SEQ ID NO.1. The preparation process of the recombinant protein antigen of Acinetobacter baumannii TonB provided in the present application is simple, the operation steps are easy to control and easy to implement, and the obtained recombinant protein of Acinetobacter baumannii TonB has high purity and high yield, and is suitable for large-scale production. The vaccine prepared using the recombinant protein antigen of Acinetobacter baumannii TonB of the present application has no toxic side effects, can produce high-titer antibodies, has good immune protection effect against Acinetobacter baumannii infection, and is suitable for preparing specific antibodies.

The present invention discloses a fusion protein of Fel D1 and Fel D4 and its application. The present invention obtains the fusion protein of Fel D1 and Fel D4 by prokaryotic expression. The fusion expressed protein greatly simplifies the operation procedures in terms of inducing protein expression, purification, concentration and immunization, and reduces the economic cost. The present invention provides a method for preparing egg yolk antibodies. The egg yolk antibodies obtained by immunizing laying hens with fusion proteins can react with Fel D1 and Fel D4 respectively, and the titer is higher than that of a single antigen protein immunization group and a combined immunization group. The present invention also provides a method for preparing a functional cat food. Egg yolk powder is added to the cat food in a certain proportion. After feeding for a period of time, the content of Fel D1 and Fel D4 in the cat's hair and saliva is significantly reduced, and the cat food prepared by the fusion protein egg yolk antibody can resist Fel D1 and Fel D4 at the same time, and the blocking effect is significantly improved.

The invention provides an application of tauroursodeoxycholic acid or an analogue thereof in preparation of an immunopotentiator of a vaccine, and the immunopotentiator. The application finds that tauroursodeoxycholic acid is an effective active component capable of activating immunity, enhancing antibody titer and shortening antibody generation reaction time, and can be widely applied to various vaccine immune processes. The bile acid metabolite and the derivative of the bile acid metabolite, which are analogues of tauroursodeoxycholic acid, also have immunological enhancement activity according to structural similarity.

The application discloses a method for efficiently extracting heparin sodium from biological materials, and the method comprises the following steps: cleaning and crushing the raw material at low temperature; adding poloxamer, ammonium sulfate and complex enzymes to perform synergistic enzymolysis under mild and neutral conditions; after the reaction is completed, the temperature is increased to above the cloud point of the polymer, liquid-liquid two-phase separation is triggered, fat-soluble impurities are synchronously removed, and the water phase rich in heparin sodium is collected; after the water phase is purified through ion exchange, concentration, alcohol precipitation and vacuum drying are sequentially performed, then vibration screening and low-temperature drying are performed, and finally, high-purity heparin sodium powder is obtained. Through the intelligent phase change characteristics of the temperature-sensitive polymer, the high-efficiency enzymolysis and primary purification are coupled, the yield and purity of heparin are significantly improved, the high-salt, strong-alkali or high-temperature conditions in the traditional process are avoided, the biological activity of the product is effectively protected, and the yield is improved.

The present invention belongs to the field of genetic engineering technology, and specifically relates to an anti-ASFV P30 protein monoclonal antibody and its application. The present invention provides an anti-ASFV P30 protein monoclonal antibody, wherein the anti-ASFV P30 protein monoclonal antibody has a heavy chain sequence as shown in SEQ ID NO: 1 and a light chain sequence as shown in SEQ ID NO: 2. The anti-ASFV P30 protein monoclonal antibody of the present invention not only has high specificity and sensitivity, but also has a simple preparation process and low cost, and provides a new and powerful tool for the rapid diagnosis of ASFV.

The present invention relates to the field of antibody technology, and specifically to an anti-Beclin1 antibody or an antigen-binding fragment thereof and an application thereof. The anti-Beclin1 antibody or the antigen-binding fragment thereof provided by the present invention can specifically bind to the Beclin1 protein, has a high titer, and has a high affinity for Beclin1. The antibody can achieve specific, sensitive and accurate detection of Beclin1, and has good application prospects in Beclin1 detection.

The present invention discloses a recombinant streptavidin, a coding gene, a recombinant plasmid and a genetic engineering bacterium and an application thereof. The amino acid sequence of the recombinant streptavidin is shown in SEQ ID NO.1, and the coding gene sequence thereof is shown in SEQ ID NO.5. The recombinant streptavidin is successfully expressed in Escherichia coli by gene recombination technology after sequence modification and addition of a polypeptide. The streptavidin has good specificity and high titer. The recombinant streptavidin is applied as an amplification system to a colloidal gold antigen detection kit, has the advantages of high specificity, high sensitivity and good stability, meets the requirements of a colloidal gold chromatography detection kit, and can be applied as an amplification system to a chromatography detection reagent.

The present invention relates to arni agents, for example double-stranded arni agents, which target the transthyretin (ttr) gene and methods of using such arni agents to treat or prevent diseases associated with ttr.

The invention relates to the field of preparation of poultry vaccines, in particular to a triple vaccine for avian yellow glands and a preparation method thereof, and the triple vaccine for avian yellow glands comprises 90-95 parts of mineral oil; 5 to 20 parts of a surfactant; 2-8 parts of a complexing agent; 1-10 parts of a divalent inorganic salt; 30-50 parts of a first virus liquid containing inactivated avian influenza virus; 30-40 parts of a second virus liquid containing inactivated fowl adenovirus; 40-60 parts of a third virus liquid containing inactivated chicken flavivirus; 5 to 10 parts of span-80; 5 to 10 parts of tween-80; and 1-3 parts of aluminum stearate. The vaccine prepared by the invention does not generate any adverse reaction on chickens, is high in experimental safety, and can induce high-level neutralizing antibodies in immunized chickens, which indicates that the immunized chickens can effectively resist virus attacks of chicken flavivirus, avian influenza and fowl adenovirus.

The invention relates to the technical field of feed additives, in particular to a protective bacteriostatic acidifier and a preparation method thereof. The acidifying agent is prepared by the method. The method comprises the following steps: crushing benzoic acid to a target particle size; uniformly mixing fumaric acid with benzoic acid with a target particle size to obtain a mixture; uniformly mixing the mixture, an auxiliary agent and water to prepare prefabricated particles; rolling the prefabricated particles to obtain spherical particles; carrying out drying treatment on the spherical particles; screening the dried spherical particles, and selecting the spherical particles with the required particle size as pellet cores; and coating the pellet core with the hot-melted coating material to prepare the protective antibacterial acidifying agent. The problem that the titer of benzoic acid cannot be improved due to the fact that existing coated benzoic acid is not protected by other acidifying agents can be solved.

The invention relates to the technical field of biology, and particularly discloses a hybridoma cell strain capable of secreting a pigment epithelium-derived factor monoclonal antibody as well as the monoclonal antibody and application of the hybridoma cell strain, and the hybridoma cell strain comprises a hybridoma cell strain JD01 # 1-E6 with the preservation number of GDMCC No: 64528 or a hybridoma cell strain JD01 # 3-B11 with the preservation number of GDMCC No: 64529. Two monoclonal antibodies aiming at different antigen epitopes of the pigment epithelium-derived factor are obtained by obtaining the hybridoma cell strain secreting the monoclonal antibody resisting the pigment epithelium-derived factor, and the specificity, the affinity and the titer of the monoclonal antibodies all meet the detection requirements; the content of the pigment epithelium-derived factor in serum or plasma can be detected through pairing, and the method can be applied to products for detecting change of the content of the pigment epithelium-derived factor or diagnosing diseases characterized by abnormal expression of the pigment epithelium-derived factor.

The invention provides a collagenase composition. The collagenase composition comprises type I collagenase, type II collagenase, clostridium protease and metalloproteinase. The collagenase composition comprises the following components in parts by mass: more than 75 parts of collagenase, 1-20 parts of metalloprotease and 0.05-3.0 parts of clostridium protease, and the mass ratio of the metalloprotease to the clostridium protease is 2-30. The collagenase composition is high in titer, good in stability and excellent in treatment effect on diseases (especially intervertebral disc protrusion).

The application discloses a tylosin A high-yield engineering strain and application thereof, and belongs to the field of genetic engineering and fermentation technology. The strain is obtained by integrating a carbon mycose synthesis gene module (M14) overexpression cassette driven by a constitutive strong promoter into a genome and knocking out a negative regulation gene tylQ , so that the yield is greatly improved. Experiments show that the yield of the engineering strain in FFM culture medium reaches 1183 mg / L, which is 10 times that of a wild type; the yield can reach 1491.5 mg / L after adding alpha-ketoglutaric acid, and the genetic stability is good. The 5L fed-batch fermentation titer reaches 5.63 g / L. The application provides an efficient and stable industrial strain for large-scale production of tylosin A.

The present invention provides a polypeptide sequence, a polyclonal antibody mixture obtained by immunizing an animal with the polypeptide sequence, a latex microsphere prepared by the polyclonal antibody mixture, and the use of the latex microsphere in extracting and separating exosomes for the treatment of depression. Preferably, the exosomes are exosomes for separating depression. The present invention also provides a method for preparing exosomes for the treatment of depression. The present invention obtains polyclonal antibodies with a high affinity for cell exosomes, and uses them as core raw materials to make latex microspheres for exosome separation and preparation. By optimizing the affinity of the coated antibodies of the latex microspheres, the efficiency of exosome separation and preparation is improved.

The invention relates to the technical field of microorganisms. The invention discloses a method for improving the titer of clostridium perfringens bacteriophage, which is characterized by comprising the following steps: S1, seed activation; s2, seed amplification; s3, expanded production of a fermentation tank: inoculating the host bacteria solution prepared in the step S2 into a fermentation medium, carrying out anaerobic culture for 0-3 hours at the temperature of 40-45 DEG C and the rotating speed of 10-30 rpm, then inoculating the bacteriophage proliferation liquid prepared in the step S2, carrying out anaerobic condition culture for 0.5-2 hours at the temperature of 35-40 DEG C and the rotating speed of 40-60 rpm, then raising the temperature to 40-45 DEG C and the rotating speed of 10-20 rpm, maintaining the tank pressure to 0.5-1.0 MPa, and carrying out fermentation for 2-3 hours at the temperature of 35-40 DEG C and the rotating speed of 40-60 rpm. Performing anaerobic culture for 4-6 hours, ending fermentation, and regulating the pH value on line. The invention also provides a bacteriophage product. According to the method for improving the titer of the clostridium perfringens phage provided by the invention, by improving the problem of pH drop in the production process, the production efficiency is improved, the stability of the clostridium perfringens phage in the finished product fermentation liquor is improved, and the storage period of the clostridium perfringens phage product in a normal-temperature environment is prolonged.

The invention belongs to the technical field of agricultural biology, and relates to a monoclonal antibody and application thereof in detection of pepper vein mottle virus, the monoclonal antibody for detection of pepper vein mottle virus comprises a first monoclonal antibody and / or a second monoclonal antibody; wherein the first monoclonal antibody is generated by a first hybridoma cell strain, the second monoclonal antibody is generated by a second hybridoma cell strain, the preservation number of the first hybridoma cell strain is CCTCC (China Center For Type Culture Collection) NO.C2024333, and the preservation number of the second hybridoma cell strain is CCTCC NO.C2024334. The monoclonal antibody has the advantages of strong specificity, high sensitivity, high titer, accurate and quantitative detection of the capsicum vein mottle virus in different organs of crops, accurate and reliable identification result, and high sensitivity.